AnalystBro Research
Research
Company valuation reports, peer comparisons, results notes, industry reports and macro views, built from company filings and official data and independently reviewed before publishing. Company reports show their full model as view-only sheets. Facts and estimates, not investment advice.
4 articles.
Company · DSE:SUNLIFEINS · Life insurance · Analysis · 29 Oct 2026
Sunlife Insurance: gross premium of BDT 186.7m in 2025 and a life fund of BDT 533.7m, both the lowest of seven years
Gross premium fell 21.5% in 2025 after a 69.5% fall in 2024. The life fund was BDT 533.7m at Dec-2025 and BDT 469.4m at Sep-2026 (DSE-announced). The auditor's report carries three emphasis of matter paragraphs and states the opinion is not modified; the board recommended no dividend for 2025.
Company · DSE:RUPALILIFE · Life insurance · Analysis · 29 Oct 2026
Rupali Life Insurance: gross premium of BDT 2.05bn in 2025, the lowest of seven years, and a qualified audit for a second year
Gross premium fell 6.1% in 2025 and first year premium was BDT 720.2m. The life fund closed 2025 at BDT 5,008.9m and was BDT 4,789.9m at Sep-2026 after deficits in each of the first three quarters. The auditor qualified the opinion on cash at bank (BDT 419.0m of unreconciled items) and an agent balance of BDT 249.0m with no provision.
Company · DSE:SANDHANINS · Life insurance · Analysis · 29 Oct 2026
Sandhani Life Insurance: the life fund shrank for eight years to 2024 and grew 2.3% in 2025; the 12% dividend took all of the surplus
Gross premium grew 1.1% to BDT 2,468m in 2025 while first-year premium fell for a third year; claims dropped to 73.7% of premium, the yield on the fund was 7.01%, the lowest in ten years, and EPS was BDT 1.20, equal to the cash dividend. The stock trades at 18.5x EPS and 1.23x NAV.
Company · DSE:NATLIFEINS · Life insurance · Analysis · 29 Oct 2026
National Life Insurance: a BDT 70bn life fund that grew 17% in 2025, but shareholders earn only the surplus slice, BDT 3.70 a share
Gross premium rose 11.1% to BDT 23.4bn in 2025 and expenses stayed 12.0% under the IDRA limit; EPS is set by the actuary's surplus split (6.5% to shareholders in 2025) and H1 2026 maturity claims rose 50%. The stock trades at 24.4x EPS and 1.60x NAV.